-
Mashup Score: 3Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day - 1 month(s) ago
Teva outlines acceleration path into a leading biopharma company Innovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO ® (deutetrabenazine), AJOVY ® (fremanezumab), UZEDY ® (risperidone) and late-stage pipeline with blockbuster potential Reaffirming 2027 financial targets, including 30% operating profit margin, driven by innovative growth and transformation programs TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation Strategy Day, to launch the acceleration phase of its “Pivot to Growth” strategy and to discuss portfolio priorities as it evolves into a global biopharmaceutical leader. The event, led by President and CEO Richard Francis and members of Teva’s executive management team, will outline the company’s strategy, progress and roadmap to deliver sustained shareholder value through 2030 and beyond. Presentations begin at 8:30
Source: ir.tevapharm.comCategories: General Medicine NewsTweet
-
Mashup Score: 8Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy - 2 month(s) ago
Press to close the select your country window or navigate to it’s content. TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody’s Investor Services (“Moody’s”) has raised the company’s corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody’s report cites the Company’s strengths which include significant global scale, ongoing growth in the company’s branded franchises, stabilization of the company’s generics
Source: www.tevapharm.comCategories: General Medicine NewsTweet-
Today @moodysratings has raised Teva’s corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Read the PR: https://t.co/FenZEACb6q $Teva
-
-
Mashup Score: 11Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved - 2 month(s) ago
For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration. Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%. AUSTEDO ® – shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion. AJOVY ® – global revenues of $139 million in Q1 2025, an increase of 26% in local currency terms compared to Q1 2024. Reaffirming $600M 2025 revenue outlook. UZEDY ® continues strong momentum – global revenues of $39 million in Q1 2025. The generics business grew across all regions – increased by 5% in the U.S., 1% in Europe and 2% in
Source: ir.tevapharm.comCategories: General Medicine NewsTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q1 2025 business results. Forward-looking statements are subject to the cautionary note included in our Q1 2025 press release. https://t.co/BNmluAKmNx #QuarterlyResults #Earnings $Teva https://t.co/mRpNmN5N0z
-
-
Mashup Score: 11Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved - 2 month(s) ago
For an accessible version of this Press Release, please visit www.tevapharm.com On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration. Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%. AUSTEDO ® – shows continued strong growth, with worldwide revenues of $411 million in Q1 2025, an increase of 39% in local currency terms compared to Q1 2024; increasing 2025 full-year revenue outlook from ~$1.9-2.05 billion to $1.95-2.05 billion. AJOVY ® – global revenues of $139 million in Q1 2025, an increase of 26% in local currency terms compared to Q1 2024. Reaffirming $600M 2025 revenue outlook. UZEDY ® continues strong momentum – global revenues of $39 million in Q1 2025. The generics business grew across all regions – increased by 5% in the U.S., 1% in Europe and 2% in
Source: ir.tevapharm.comCategories: General Medicine NewsTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q1 2025 business results. Forward-looking statements are subject to the cautionary note included in our Q1 2025 press release. https://t.co/BNmluAKmNx #QuarterlyResults #Earnings $Teva https://t.co/mRpNmN5N0z
-
-
Mashup Score: 2Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States - 3 month(s) ago
Press to close the select your country window or navigate to it’s content. EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive EPYSQLI will be available at a 30% discount of the Wholesale Acquisition Cost (WAC) of the reference product, Soliris ® (eculizumab), making it one of the
Source: www.tevapharm.comCategories: General Medicine NewsTweet-
#NEWS: Teva and @SamsungBioepis announce launch of #raredisease #biosimilar in the U.S. Learn more: https://t.co/5mgY3TkiKJ $Teva https://t.co/QSXN8LB0FE
-
-
Mashup Score: 3Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention - 3 month(s) ago
Press to close the select your country window or navigate to it’s content. If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, addressing the high unmet need for effective treatments AJOVY is currently the only anti-CGRP treatment for migraine prevention in adults in the U.S. that is available in both quarterly and monthly dosing options 1 These
Source: www.tevapharm.comCategories: General Medicine NewsTweet-
We are happy to share more on our continued commitment to support the care of #migraine patients. Read more here: https://t.co/fmzyAPr5Sz #TevaUSA https://t.co/HUfF6gpTjg
-
-
Mashup Score: 2
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO ® – exceeding $1.6 billion in revenues, surpassing 2024 outlook; AJOVY ® – global annual revenues of $507 million, an increase of 18% in local currency terms compared to 2023; UZEDY ® revenues of $117 million in 2024 surpassing $100M outlook; Generics business continues to grow across all segments, with increases of 15% in the U.S., 6% in Europe and 15% in International Markets, all in local currency terms compared to 2023; First-to-market launches including first generic version of Sandostatin ® LAR Depot and liraglutide injection 1.8mg (an authorized generic of Victoza ® ); On January 2025, Teva entered into a license and supply agreement, for a proposed generic GLP1 in the U.S., Europe and additional countries; Biosimilar pipeline is expanding, and now includes 18 assets, including SELARSDI TM , which is expected to launch in the U.S. in the first quarter of 2025; and our
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q4 and FY 2024 business results. https://t.co/AtmmTiDSLj Forward-looking statements are subject to the cautionary note included in our Q4 2024 press release. #QuarterlyResults #Earnings… https://t.co/W86eQWC9fq https://t.co/Rl5UMraqAf
-
-
Mashup Score: 2
Richard Francis, Teva Pharmaceuticals CEO, joins ‘Money Movers’ to discuss the company’s quarterly earnings results, drug price negotiations, and much more.
Source: www.cnbc.comCategories: General Medicine News, PayerTweet-
Teva CEO Richard Francis spoke with @moneymoverscnbc about our Q4 and full year 2024 performance, marking our second year of consecutive growth. Watch the full interview here: https://t.co/hrIFOem22r Forward-looking statements are subject to the cautionary note included in our… https://t.co/VZAoUNQ7VN https://t.co/kSlJ8rges5
-
-
Mashup Score: 2
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO ® – exceeding $1.6 billion in revenues, surpassing 2024 outlook; AJOVY ® – global annual revenues of $507 million, an increase of 18% in local currency terms compared to 2023; UZEDY ® revenues of $117 million in 2024 surpassing $100M outlook; Generics business continues to grow across all segments, with increases of 15% in the U.S., 6% in Europe and 15% in International Markets, all in local currency terms compared to 2023; First-to-market launches including first generic version of Sandostatin ® LAR Depot and liraglutide injection 1.8mg (an authorized generic of Victoza ® ); On January 2025, Teva entered into a license and supply agreement, for a proposed generic GLP1 in the U.S., Europe and additional countries; Biosimilar pipeline is expanding, and now includes 18 assets, including SELARSDI TM , which is expected to launch in the U.S. in the first quarter of 2025; and our
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q4 and FY 2024 business results. https://t.co/AtmmTiDSLj Forward-looking statements are subject to the cautionary note included in our Q4 2024 press release. #QuarterlyResults #Earnings… https://t.co/W86eQWC9fq https://t.co/Rl5UMraqAf
-
-
Mashup Score: 2Teva CEO on Drug Pricing, Generics, Supply Shortages - 6 month(s) ago
Teva Pharmaceuticals CEO Richard Francis reflects on company performance in 2024, drug pricing, getting more drugs to market and supply shortages of the drug Adderall. He speaks to “Bloomberg Open Interest” from the JPMorgan Healthcare Conference. (Source: Bloomberg)
Source: www.bloomberg.comCategories: General Medicine News, PayerTweet-
Speaking with Bloomberg at the J.P. Morgan Healthcare Conference 2025, Teva President and CEO Richard Francis reflected on the company’s exceptional performance in the first three quarters of 2024. Watch the full interview here: https://t.co/K9xVd1AhWe #TevaUSA #JPM25 https://t.co/pSd2vHaxAE
-
💫 It's Teva Innovation & Strategy Day 💫 After 9 consecutive quarters of growth, we are now entering the acceleration phase of our transformation into a leading biopharma company. Today we're sharing our roadmap and strategic priorities. Learn more: https://t.co/2Ns5xUyNuu https://t.co/iLMhGDgvx9